Research ArticleArticle
14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
Walter P. Maksymowych, Gilles Boire, Dirkjan van Schaardenburg, Stephanie Wichuk, Samina Turk, Maarten Boers, Katherine A. Siminovitch, Vivian Bykerk, Ed Keystone, Paul Peter Tak, Arno W. van Kuijk, Robert Landewé, Desiree van der Heijde, Mairead Murphy and Anthony Marotta
The Journal of Rheumatology July 2015, jrheum.141385; DOI: https://doi.org/10.3899/jrheum.141385
Walter P. Maksymowych
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Gilles Boire
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Dirkjan van Schaardenburg
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Stephanie Wichuk
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Samina Turk
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Maarten Boers
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Katherine A. Siminovitch
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Vivian Bykerk
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Ed Keystone
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Paul Peter Tak
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Arno W. van Kuijk
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Robert Landewé
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Desiree van der Heijde
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Mairead Murphy
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Anthony Marotta
From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK. This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada. W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp. Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca. Accepted for publication May 14, 2015.
Article Information
jrheum.141385
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online July 15, 2015.
Article Versions
- You are currently viewing a Latest version of this article (July 15, 2015 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2015 The Journal of Rheumatology
Author Information
- Walter P. Maksymowych,
- Gilles Boire,
- Dirkjan van Schaardenburg,
- Stephanie Wichuk,
- Samina Turk,
- Maarten Boers,
- Katherine A. Siminovitch,
- Vivian Bykerk,
- Ed Keystone,
- Paul Peter Tak,
- Arno W. van Kuijk,
- Robert Landewé,
- Desiree van der Heijde,
- Mairead Murphy and
- Anthony Marotta
- From the Department of Medicine, University of Alberta, Edmonton,Alberta; Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec; Mount Sinai Hospital, University ofToronto, Toronto; Augurex Life Sciences Corp., North Vancouver, BritishColumbia, Canada; Jan van Breemen Research Institute/Reade; VU University Medical Center; Academic Medical Center, Amsterdam;Division of Rheumatology, Leiden University Medical Center, Leiden, theNetherlands; Hospital for Special Surgery, New York, New York, USA;University of Cambridge, Cambridge; GlaxoSmithKline Inc., Brentford,UK.
This investigation was solely funded by Augurex Life Sciences Corp.,North Vancouver, British Columbia, Canada.
W.P. Maksymowych, MD, Professor of Medicine, Department of Medicine, University of Alberta; G. Boire, MD, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke; D. van Schaardenburg, MD, Janvan Breemen Research Institute/Reade; S. Wichuk, MD, Department ofMedicine, University of Alberta; S. Turk, MD, Jan van Breemen Research Institute/Reade; M. Boers, MD, Professor of Clinical Epidemiology, VU University Medical Center; K.A. Siminovitch, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, Hospital for Special Surgery; E. Keystone, MD, Professor of Medicine, Mount Sinai Hospital, University of Toronto; P.P. Tak, MD, Academic Medical Center,and University of Cambridge, and GlaxoSmithKline Inc.; A.W. van Kuijk, MD; Robert Landewé, MD, Academic Medical Center; D. van der Heijde, MD, Division of Rheumatology, Leiden University Medical Center; M. Murphy, PhD; A. Marotta, PhD, Augurex Life Sciences Corp.
Address correspondence to Dr. W.P. Maksymowych, Professor of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, Alberta T6G 2S2, Canada. E-mail: walter.maksymowych@ualberta.ca.
Accepted for publication May 14, 2015.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
Walter P. Maksymowych, Gilles Boire, Dirkjan van Schaardenburg, Stephanie Wichuk, Samina Turk, Maarten Boers, Katherine A. Siminovitch, Vivian Bykerk, Ed Keystone, Paul Peter Tak, Arno W. van Kuijk, Robert Landewé, Desiree van der Heijde, Mairead Murphy, Anthony Marotta
The Journal of Rheumatology Jul 2015, jrheum.141385; DOI: 10.3899/jrheum.141385
14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
Walter P. Maksymowych, Gilles Boire, Dirkjan van Schaardenburg, Stephanie Wichuk, Samina Turk, Maarten Boers, Katherine A. Siminovitch, Vivian Bykerk, Ed Keystone, Paul Peter Tak, Arno W. van Kuijk, Robert Landewé, Desiree van der Heijde, Mairead Murphy, Anthony Marotta
The Journal of Rheumatology Jul 2015, jrheum.141385; DOI: 10.3899/jrheum.141385